Previous Close | 3.5800 |
Open | 3.6000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 3.5600 - 3.7000 |
52 Week Range | 2.8200 - 7.5000 |
Volume | |
Avg. Volume | 36,654 |
Market Cap | 58.379M |
Beta (5Y Monthly) | -0.29 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.8500 |
Earnings Date | Apr 29, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.10 |
Subscribe to Yahoo Finance Plus to view Fair Value for ALVAL.PA
Valbiotis (FR0013254851 - ALVAL, PEA/SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the results of the international Phase II/III REVERSE-IT study, demonstrating TOTUM•63's impressive efficacy on key markers of glucose metabolism, with efficacy results comparable to those of some leading anti-diabetic drugs,
LA ROCHELLE, France, May 22, 2023--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible) (Paris:ALVAL), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the large success of the REVERSE-IT Phase II/III clinical study on TOTUM•63. Conducted in 636 prediabetic and untreated type 2 diabetic patients (early stage), this international, multicentric, randomized and pla
LA ROCHELLE, France, May 03, 2023--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces its Combined Annual Shareholders Meeting was held on May 2, 2023 at Espace Encan, La Rochelle, under the chairmanship of Sébastien PELTIER, Chairman of the Board of Directors.